secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2026-08-04T20:10:21+00:00
Accession:  0001493152-26-035995
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx to highlight TAMP platform at JonesTrading KOL webinar on Aug 13, 2026
-------------------------------------------------------------------------------

- RenovoRx to participate in JonesTrading KOL webinar on pancreatic cancer on Aug 13, 2026 at 1:30 p.m. ET.
- RenovoCath sales of ~$1.1M in 2025 and record $563K in Q1 2026.
- Full enrollment in Phase III TIGeR-PaC trial expected very near term; final data readout mid to late 2027.
- IAG (intra-arterial gemcitabine via RenovoCath) has Orphan Drug Designation for pancreatic and bile duct cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/0001493152-26-035995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer